Planview Completes Acquisitions of Clarizen and Changepoint
23.2.2021 17:01:00 EET | Business Wire | Press release
Planview, a global leader in Portfolio Management and Work Management solutions, today announced it has closed its previously announced acquisitions of Clarizen and Changepoint, two leading Project Portfolio Management (PPM) providers.
“For more than three decades, Planview has been pioneering the technologies and best practices that the world’s best companies use to reimagine the ways they plan and manage work,” said Greg Gilmore, CEO of Planview. “Together, Planview, Clarizen, and Changepoint offer a portfolio for the modern enterprise, providing organizations the visibility and agility needed to drive more innovation, execute on their strategic objectives, and capitalize on compelling opportunities. We are thrilled to welcome Clarizen and Changepoint into the extended Planview family.”
As a result of the transaction, Planview, Clarizen and Changepoint customers will benefit from being part of a premier community of PMOs, PPM, and Professional Services Automation (PSA) practitioners. The expanded portfolio of solutions will provide customers the tools and resources to better strategically plan and deliver on their most important initiatives. The combination will be transformative for the industry and has received strong feedback from customers to date.
The nature of work has changed significantly in recent years, causing leaders across industries to rethink how to best strategically plan, execute, and empower teams in today’s all-digital world. This shift has placed a spotlight on the growing importance and strategic value of Portfolio Management, Work Management and Enterprise Agile Planning capabilities, as evidenced by the recent wave of IPOs, consolidation, and acquisitions of several key players in this category. Planview’s rich history in the space, acquisitions of Clarizen and Changepoint, its comprehensive product offerings, and its significant growth position have placed the company at the forefront of this global market.
“This acceleration of PPM and work management acquisitions indicates the vital need for companies to adapt and manage the way they work in the face of fast changes to the global economy and competitive landscapes,” said Melinda Ballou, Research Director, Agile ALM, Quality & Portfolio Strategies at IDC. “The need to respond adaptively and collaboratively to unexpected change will endure. This dual acquisition on the part of Planview is a bold move to scale the company in several related and growing market areas, and with effective integration and alignment, we would expect more strategic positioning for Planview moving forward.”
The close of the transactions closely follows Planview’s acquisition in December 2020 by TPG Capital and TA Associates, whose investment has focused on accelerating Planview’s growth and vision for Agile and PPM for Enterprises. Clarizen and Changepoint are the company’s largest acquisitions to date and represent an important first step in Planview’s growth strategy for 2021.
Planview is also coming off of its strongest financial year in company history, capped by a fourth quarter that included its largest customer deal and most successful financial quarter on record, as well as a significant uptick in customer adoption of Planview’s Lean and Agile Delivery solutions. To learn more, visit: www.planview.com.
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 1000 employees supporting 4,500 customers and 1.3 million users worldwide. For more information, visit: the Planview website at www.planview.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005335/en/
Contact information
Planview
Leslie Marcotte
719-439-4921
lmarcotte@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom